XML 165 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Gross value          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases € 1,554 [1]   € 3,112 [1]   € 571
Gross value | Products, trademarks and other rights          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases 444 [1]   1,970 [1]   195
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Teva Pharmaceuticals          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases | $       $ 500  
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Janssen Pharmaceuticals, Inc          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases | $       $ 175  
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Novavax          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases | $   $ 500      
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Corxel Pharmaceuticals          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases | $   $ 300      
Goodwill          
Disclosure of reconciliation of changes in goodwill [line items]          
Beginning balance 49,404   49,892   48,056
Acquisitions during the period 0   475 [2]   609
Other movements during the period [3] (351)   (90)   (258)
Currency translation differences 1,586   (873)   1,485
Increase (decrease) through reclassification, intangible assets other than goodwill [4] (7,255)        
Ending balance € 43,384   € 49,404   € 49,892
[1] (f)This line mainly comprises:
In 2023:
–the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus
(nirsevimab) (see Note C.2.);
–an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-
commercialization of TEV’574;and
–an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against
extra-intestinal pathogenic strains of E-Coli.
In 2024:
–an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the
co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and
–an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and
commercialization rights to aficamten in China.
[2] (c)The final purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) of
€774 million as of the acquisition date (September 29, 2023) and of goodwill measured at €484 million as of the acquisition date (see Note D.1.).
[3] (a)This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, including in 2024 the
allocated goodwill relating to the divestment of the Enjaymo activity to Recordati (see Note D.1.). For 2022, this line includes the loss of control of
EUROAPI (see Note D.1.).
[4] (b)The Opella goodwill is presented within Assets held for sale (see Note D.1.).